Tech Company Financing Transactions
Hexagon Bio Funding Round
Hexagon Bio, based in Menlo Park, secured $77.3 million in investment from 8VC, Canada Pension Plan Investment Board and Nextech.
Transaction Overview
Company Name
Announced On
2/13/2023
Transaction Type
Venture Equity
Amount
$77,300,000
Round
Series B
Investors
8VC (Alex Kolicich)
Canada Pension Plan Investment Board
The Column Group (David Goeddel)
Two Sigma Ventures (Dusan Perovic)
Proceeds Purpose
Hexagon plans to use proceeds from the Series B round to continue to grow its team across multiple disciplines as it expands the reach and capabilities of its platform, and advances its initial programs focused on oncology and infectious disease toward development candidate nomination.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1490 O'Brien Dr. E
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Hexagon Bio's mission to identify medicines encoded in the global metagenome, and bring them to patients. While nature's molecules have proven to be a rich source of potent medicines, their translation has been laborious and hindered by the lack of mechanistic understanding of the intended target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maureen Hillenmeyer
Founder
Colin Harvey
Founder
Brian Naughton
Founder
Yi Tang
Vice President
James Li
VP - Bus. Development
Sofia Touami
VP - Engineering
Andrew Aymeloglu
Browse more venture capital transactions:
Prev: 2/13/2023: Via venture capital transaction
Next: 2/13/2023: Complete Solaria venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs